How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

Need help?

Contact us

NiKang Therapeutics® Presents Discovery of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader for Cancer Therapy at SABCS 2025

calendar_today December 11, 2025 person Elizabeth Aspinall domain nikang-therapeutics

See the press release on Business Wire

open_in_new Read original post